The Optimization of Conditioning Regimen for HLA Matched HSCT in SAA
Launched by PEKING UNIVERSITY PEOPLE'S HOSPITAL · Oct 1, 2023
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying different treatment plans to improve outcomes for patients with severe aplastic anemia (SAA) who are receiving a type of stem cell transplant called hematopoietic stem cell transplantation (HSCT). The researchers want to find out which conditioning regimens—the treatments given before the transplant—work best to minimize complications and improve survival rates. They will compare a few different combinations of medications to see which one helps patients avoid issues like mixed chimerism, where the body doesn’t fully accept the donor cells.
To participate in this trial, you need to be diagnosed with severe or very severe aplastic anemia and have a matched donor, either a sibling or someone unrelated. You also need to be under 50 years old, have no serious infections or organ damage, and be able to give informed consent. If you join, you’ll be monitored closely throughout the study to assess how well the treatment works and to ensure your safety. This trial is currently open for recruitment, and everyone is welcome to apply, regardless of gender.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Diagnosed as SAA/vSAA
- • 2. Indication for hematopoietic stem cell transplantation
- • 3. Available HLA matched sibling or unrelated donor
- • 4. No active infection
- • 5. No serious organ damage: liver and kidney function (ALT and AST \< 2.5 times normal value, normal renal function, no cardiac insufficiency)
- • 6. Signed informed consent
- • 7. High risk factors of mixed chimerism, at least one of the following
- • 1. Age \< 18 years old
- • 2. Ferritin level ≥2500ng/ml before transplantation
- Exclusion Criteria:
- • 1. Age \> 50 years old
- • 2. ECOG≥3
- • 3. Active infections that were difficult to control
- • 4. Severe liver and kidney dysfunction
- • 5. Mental illness
- • 6. Not signing the informed consent
- • 7. pregnant or lactating women
- • 8. Any condition considered by the investigators to be unsuitable for enrollment
About Peking University People's Hospital
Peking University People's Hospital is a leading clinical research institution in China, renowned for its commitment to advancing medical knowledge and improving patient care through innovative clinical trials. Affiliated with Peking University, the hospital integrates cutting-edge research, comprehensive healthcare services, and a multidisciplinary team of experts to facilitate the development of new therapies and medical interventions. With a strong focus on patient safety and ethical standards, Peking University People's Hospital is dedicated to conducting rigorous clinical trials that contribute to the global medical community and enhance the quality of life for patients.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Beijing, Beijing, China
Patients applied
Trial Officials
Xiao-Jun Huang
Principal Investigator
Peking University People's Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported